Waiting for : The consensus of the first CMV management experts in the field of allogeneic hematopoietic stem cell transplantation is coming!

Cytomegalovirus (CMV) infection is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which seriously threatens the prognosis and health

This year, based on Evidence-based medical evidence in China and with reference to relevant international guidelines, experts in relevant fields in China organized by the Stem Cell Application Group of the Hematology Branch of the Chinese Medical Association to jointly compile the first domestic CMV infection management expert consensus in the field of allo-HSCT - "Chinese Expert Consensus on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Patients (2022 Edition)" (hereinafter referred to as the "Consensus"), which will be published

On September 2, 2022, the press conference of "China Expert Consensus on CYTOME Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Patients (2022 Edition)" was successfully held in Qingdao, and the expert group of the Consensus Editorial Board and many domestic experts in the field of blood witnessed the release of

The consensus conference was chaired by Professor Huang Xiaojun of Peking University People's Hospital, President Dong Wenge of Chinese Journal of Hematology as special guests, Professor Wu Depei of the First Affiliated Hospital of Soochow University, Professor Liu Qi of Southern Hospital of Southern Medical University, Professor Zhang Xiaohui of Peking University People's Hospital, Professor Sun Zimin of the First Affiliated Hospital of University of Science and Technology of China, professor Song Yongping of the First Affiliated Hospital of Zhengzhou University as the moderator of the conference, and Professor Xu Lanping of Peking University People's Hospital as expert speakers.

President of the General Assembly

Professor Huang Xiaojun, Peking University People's Hospital

"In recent years, China has made remarkable achievements in the scientific research and clinical field of blood diseases, and China's hematopoietic stem cell transplantation level has reached the international leading level, but CMV infection, as a common complication of allo-HSCT, poses a serious threat to the treatment effect of transplantation and the life of patients, and CMV control in the process of hematopoietic stem cell transplantation is still one of the important challenges facing it, and the clinical need for a more efficient and standardized response plan

It is a great honor to gather with all the experts today to witness the release of the first expert consensus on CMV infection management in the field of allo-HSCT, which clarifies the diagnostic criteria and treatment principles for CMV infection in transplant patients, and will provide strong support

Special guests

President of the Chinese Journal of Hematology Dong Wenge

"The Chinese Journal of Hematology implements the policy of combining theory and practice, clinical and basic, popularization and improvement, and hopes to promote the development of overall research in Hematology in China and help the health

In the past few decades, CMV infection has been a thorny medical problem, it is a great honor to participate in the preparation and release of the consensus of CMV infection management experts, I hope that through the academic platform of the Chinese Journal of Hematology, the consensus content can be transmitted to more experts in the field of allogeneic hematopoietic stem cell transplantation, helping to improve the level of diagnosis and treatment of experts in related fields, reducing the risk of CMV infection in patients, and promoting the development and progress of allogeneic hematopoietic stem cell transplantation treatment in China! It is expected that the Consensus will be published as soon as possible to benefit more clinical patients

Expert speakers

Professor Xu Lanping, Peking University People's Hospital

At the meeting, Professor Xu Lanping, an expert in the writing of consensus, shared in depth based on the background of consensus revision, consensus framework, and consensus sub-chapter details, and explained in detail the core contents

Professor Xu Lanping pointed out: "The occurrence of CMV infection after allogeneic hematopoietic stem cell transplantation is a major hidden danger to the life and health of patients, and the fatality rate of infection and its complications is very high

summary

CMV infection and related diseases are one of the important factors affecting the prognosis of allogeneic hematopoietic stem cell transplant patients, and the release of the "Chinese Expert Consensus on cytomegalovirus infection management in allogeneic hematopoietic stem cell transplant patients (2022 edition)" will provide positive guidance for clinical response to the challenge of CMV infection and guard the prognosis of allogeneic hematopoietic stem cell transplant patients, and will also play a positive role in standardizing the CMV diagnosis and treatment process of allogeneic hematopoietic stem cell transplant patients in China and the sustainable development of hematology